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Introduction: Recent research on biomarkers has made possible the diagnosis of pre-dementia and even preclinical
Alzheimer’s disease (AD), thus providing the ideal context for prevention. The aim of this study was to investigate
the epidemiology of the early stages of AD by fitting neuropathologic and epidemiological data to assess the feasibility
of prevention programs.
Methods: The study addressed primarily the construction of a discrete event simulation model of the stages of
dementia. Age was included in the mathematical functions to combine the two competitive risks that determine
the epidemiology of AD, that is, time to onset of dementia and time until death by other causes. Subsequently,
this model was calibrated to reproduce the prevalence of pathological findings associated with AD. The beginning
of the preclinical stage was taken to coincide with Thal phase 1 deposition of amyloid-beta. The duration of the
prodromal stage, marked by mild cognitive impairment, was based on a 10% annual conversion rate from this
level of impairment to dementia. The validation of prevalence figures also permitted estimation of the incidence
and duration of preclinical and prodromal stages.
Results: In Spain, half of the nearly 10 million people aged more than 60 years are in the early stages of AD; 35.9%
are in a preclinical stage, and up to 14.2% are in a prodromal stage. However, dementia will develop in only 38%
of this population. The weighted mean time to dementia was 22.0 years from the start of Thal phase 1 and
9.0 years from the start of phase 2. Results of simulation models showed a lack of correlation between clinical and
pathological classifications.
Conclusions: These findings raise questions about the feasibility of drug-based prevention strategies. Currently,
screening programs with biomarkers in the early stages of AD cannot be applied to the half of the general population
older than 60 years. Hence, intensive research is needed regarding risk factors, so that more affordable strategies may
be planned. More efficient criteria are also needed to select those subjects with mild cognitive impairment who have
an increased probability of positive screening for biomarkers (prodromal stage).Introduction
The definition of Alzheimer’s pathology and Alzheimer’s
disease (AD) has been the subject of profound con-
ceptualization [1]. The research diagnostic criteria pro-
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the clinical diagnosis could be determined on an exclu-
sionary basis and confirmed only post mortem [2]. For
more than 25 years, this approach was generally em-
braced, until advances in biomarker research reached the
clinical setting and promoted a new paradigm [3]. The
International Work Group [4] and the National Institute
of Aging–Alzheimer’s Association task force [5,6] pro-
posed new diagnostic criteria that cover all possible clin-
ical manifestations of the disease and allow a premortem
biological diagnosis to be made on the basis of positive
biomarkers. Moreover, the concept of a preclinical stage ofis is an Open Access article distributed under the terms of the Creative
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defined as the finding of positive biomarkers of amyloid
deposition with or without neurodegenerative changes [7].
Accordingly, AD is defined as a long, degenerative process
that starts with the development of specific neuropatho-
logical changes in the brain without clinical manifestations
(preclinical stage) until progression to a prodromal stage
of mild cognitive impairment (MCI) and finally to demen-
tia [1]. Available empirical information about the early
preclinical stage comes mainly from brain registries [8],
although in vivo information is now being gathered with
biomarker studies [9].
The fact that AD may now be detected in its earliest
symptomatic, or even in its asymptomatic, preclinical
stage has opened new appealing lines of research to in-
vestigate potential prevention strategies at the secondary
or tertiary level. Prevention strategies could reduce the
population burden of AD through the introduction of
disease-modifying drug treatments or intervention pro-
grams for risk-factor modification [10,11]. However, the
targets and time periods of both observational and inter-
ventional studies are too limited to estimate the long-
term impact of prevention at the general population
level, and many questions regarding feasibility remain.
The reproduction of the natural history of AD with
mathematical models has been used to predict its evolu-
tion through simulation and to evaluate the health im-
pact and cost-effectiveness of intervention programs
[12,13]. In addition, such models may help in calculating
epidemiological parameters of prevalence, incidence and
duration of disease stage [14].
The objective of this study was to estimate the epi-
demiology of early stages of AD by fitting the incidence
and prevalence with neuropathological findings of AD in
autopsies in the general population to assess the feasibil-
ity of prevention programs.
Methods
The study primarily addressed the construction of a vali-
dated model of the dementia stages on the basis of the
results of two meta-analyses that estimated the incidence
and prevalence of AD dementia in European populations
[15,16]. Subsequently, this model was calibrated to
reproduce the prevalence of pathological findings associ-
ated with AD in the population by age group, according
to the study by Braak and colleagues [8]. The epidemi-
ology of the early stages of AD was described by calculat-
ing the incidence, prevalence and duration of the
preclinical and prodromal stages. As there is currently no
empirical data to estimate these parameters in any popula-
tion, a discrete event simulation (DES) model was used to
represent the relation of AD to the Spanish population
more than 40 years old and to calculate them [14]. The
Technical Appendix (Additional file 1) contains thecomplete description of the model and its parameters.
Discrete event simulation is a flexible modeling method
characterized by the ability to represent complex behavior
within, and interactions between, individuals, populations
and their environments [17]. This study was based on a lit-
erature review and a computing model without patient in-
volvement, so no ethical approval or consent was needed.
Conceptual model
The natural history model divides AD into three clinical
stages: preclinical, prodromal and dementia [4-6]. Be-
cause the clinical classification of AD does not correlate
with the presence and density of deposits of amyloid
beta (Aβ) and tau proteins in the brain [18], the discrete
event simulation model was populated directly with
findings associated with progress of Aβ deposition [8].
Clinicopathological studies indicate that the presence of
Aβ is more specific than tau deposits for the etiology of
AD [18,19], so we reproduced in the model the evolu-
tion of neuropathological findings by Thal phases [8,20].
Braak and colleagues analyzed 2,332 brains for findings
associated with AD and estimated the presence of Aβ
deposits in terms of the Thal phases by age group [8].
From these results, we identified the beginning of the
preclinical stage of AD by Thal phase 1, which is charac-
terized by the presence of plaque-like Aβ deposits in the
temporal neocortex. The next stages showed deposits
also in the allocortex and associated areas of the neocor-
tex (Thal phases 2 and 3) or in virtually all cerebrocorti-
cal regions (Thal phase 4) [8,20]. In the representation
of the conceptual model of AD, the relevant input was
only the time from the beginning of the Thal 1 phase.
The progression of pathological findings according to
Thal phases was calculated to compare the results with
estimates based on clinical classification.
Beyond Aβ deposition, the duration of the preclinical
stage depends on different factors that still remain to
be discovered. The combination of these conditions
and the competitive risk of death from other causes
determines which individuals reach the clinical stage.
As the National Institutes of Health State-of-the-
Science Conference noted, there is currently no evi-
dence about modifiable factors causally associated with
AD [21]. However, Barnes and Yaffe identified factors
consistent with evidence of AD, such as diabetes melli-
tus, present smoking, depression, cognitive impair-
ment, physical activity and poor diet (high saturated
fat and low vegetable intake) [11]. Following their
approach in our study, we used the term risk factors
instead of risk markers to account not only for the
current scenario but also for potential future findings;
however, we stress that this use does not indicate any
demonstrated causal relationship between epidemiological
condition or behavior and AD.
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Thal phases, the duration was estimated from studies
measuring the conversion of MCI to dementia with rates
that ranged from 5 to 20% per year [18,22]. This vari-
ability derives from the heterogeneity of samples from
patients with MCI, which includes both clinical studies
(high rates) and population studies (low rates), so we ap-
plied a 10% rate that resulted in a duration of 10 years
by application of the exponential function [23].
Discrete event simulation model
The model was preloaded with the entire Spanish popu-
lation older than 40 years of age in 2009 to measure the
stage of AD in individuals in 2010. On entry into the
simulation model, individuals were characterized by the
relevant attributes of age, sex, duration until death and
duration until dementia (Figure 1). The stochastic nature
of the process meant that the individual’s behavior was
randomly determined in the model, depending on which
risk (either the development of dementia or death by
other causes) finally occurred [14,17]. Table 1 presents
the main parameters of the model.
We calculated the parameters for the Gompertz func-
tion that reproduces life expectancy by age and sex from
mortality rates in the Spanish population in 2010, as ob-
tained from the National Institute of Statistics (INE)
[24]. It was assumed that during the prodromal and pre-
clinical stages the mortality rate was the same as that in
the general population. The same procedure, but with
the incidence rates of AD dementia, allowed us to calcu-
late the parameters for the Gompertz function that set
the age of onset of dementia [15,24]. The calculated inci-
dence [15] matched the model used by Brookmeyer and
colleagues and the results of Ferri and colleagues
[12,25]. Dementia incidence was not a model input, but
the result of the interaction between two competing
risks (death or development of dementia) in cohorts of
individuals entering the preclinical stage in the model
and was used as a main result of external validation. TheFigure 1 The natural history of Alzheimer’s disease by clinical and paprevalence of dementia was the result of the combin-
ation of incidence and disease duration, and this was
also measured to validate the model. The figures used to
parameterize dementia risk function derive from studies
that may not be representative enough for ages older
than 90 years. Our model could overestimate the weight
of such a population, as risk grows over time and, with
use of the Gompertz function, reaches high levels for
older people. However, this limitation would not apply
to the early stages of AD, which are the main concern of
this work. Survival after a diagnosis of dementia was de-
termined from the study by Dodge and colleagues [26].
Once we determined the age of onset of dementia, it
was possible to identify the starting points of different
Thal phases by calibration. For each phase, we estab-
lished the time from the beginning of Aβ deposition to
dementia. The results were obtained in 2010 and
grouped by age and sex. Calibration is the process of de-
termining the values of unobservable parameters by con-
straining model output to replicate observed data [27].
The calibration step consisted of estimating the duration
of the preclinical stage by adjusting the model until it
matched the observed pattern for Thal phase 1 in the
study by Braak and colleagues [8]. Different values were
tested by calibration [27], as Thal phase 1 prevalence is a
directly unobservable parameter. Epidemiological pa-
rameters for Thal phases 2 and 3 were also calculated by
applying the same method.
Results
The model was validated by comparing the calculated
life expectancy, incidence and prevalence of the dementia
stage in 2010 with the values of Dodge and colleagues, of
Fratiglioni and colleagues and of Lobo and colleagues
(see Additional file 1) [15,16,26]. The number of individ-
uals with dementia due to AD obtained with the model
was 370,300 in 2010, which appears to correlate with the
400,000 people estimated in a review of Spanish surveys
by de Pedro-Cuesta and colleagues [28].thological classifications. Aβ, amyloid beta.
Table 1 Parameters of the model
Source Function Parameters Male Female
Time until death due to other causes INE Gompertz ln(α) −10.022 −11.922
β 0.090 0.108
Time until dementia [15] Gompertz ln(α) −17.825 −16.772
β 0.164 0.157
Dementia survival [21] Polynomic b0 30.835 42.767
b1 −0.447 −0.709
b2 0.002 0.003
Prodromal stage length [17,18] Exponential λ 10 10
INE, Spanish National Institute of Statistics.
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phases was variable, with a weighted mean of 22.0 years
for phase 1 and 9.0 years for phase 2 (Table 2). Table 3
presents the disaggregated incidence by age group in
the Spanish population according to clinical and patho-
logical classifications. The disaggregated prevalence
figures by epidemiological and pathological classifica-
tions (Table 4) highlight the huge range of early stages
of AD in the population. From the population in Spain
of nearly 10 million people older than 60 years of age,
35.9% were shown to be in a preclinical stage and
14.2% in a prodromal stage.
Figure 2 shows the percentage of individuals in each
age group according to clinical and pathological classi-
fications. The same data, but incorporating the figures
of Braak et al. for Thal phases, appear in the Technical
Annex to display the goodness of fit for results (see
Additional file 1).Table 2 Time from the start of each Thal phase to the
onset of dementia
Time until dementia from
Age Thal1 Thal2
40 to 44 45.6 22.0
45 to 49 35.3 22.0
50 to 54 31.8 21.9
55 to 59 29.8 20.5
60 to 64 28.1 18.5
65 to 69 26.6 16.7
70 to 74 23.1 13.0
75 to 79 19.0 8.7
80 to 84 14.9 4.3
85 to 89 10.8 2.1
90 to 94 6.7 1.0
95 to 99 2.9 0.9
>100 2.1 1.0
Weighted mean 22.0 9.0Discussion
One of the main findings of this research is that one-half
of the population older than 60 years of age in a devel-
oped country has some degree of Aβ deposition in the
brain. This result agrees with those from population-
based autopsy studies, such as the Medical Research
Council Cognitive Function and Aging Study that
showed 47% of nondemented subjects older than 70
years had mild, moderate or severe densities of neuritic
plaques [29]. The enormous size of such a group of af-
fected individuals is highlighted by the fact that it would
encompass 15.2% of the total Spanish population
(46,148,700 persons). Since the lifetime risk of AD at age
60 years is 19%, an intervention program targeting the
50% of subjects with Aβ deposits would include treating
68% of that population who would never reach the de-
mentia stage [30]. With use of both neuropathological
and clinicoepidemiological data, discrete event simula-
tion modeling has provided an estimate of the time lapse
between the earliest preclinical changes and the onset of
dementia. This interval is usually considered to range
from 10 to 20 years [5], but according to the model may
be more than 30 years. The findings of both high preva-
lence and prolonged asymptomatic periods have import-
ant public health implications in the study of dementia,
particularly in the prevention of AD. Salomon and col-
leagues have discussed the relevance for prevention
plans based on two different concepts of AD onset [30];
that is, whether the starting point relies on pathological
changes only [5-7] or on specific clinical manifestations
[4]. Consistent with the definition of AD onset, the same
preventive intervention can be labeled as primary when
dealing with clinical symptoms only or as secondary if
prior pathological changes are considered. In relation to
our use of Aβ deposition in the model as the marker of
the preclinical stage, we understand that primary pre-
vention interventions should be applied before the onset
of pathological changes by promoting initiation and
maintenance of good health and eliminating or modify-
ing potential risk conditions, if these are ever
Table 3 Incidence of new cases of Alzheimer’s disease by 1,000 person-years and by clinical and pathological
classifications
Incidence/1,000 person-years
Clinical classification Pathological classification
Age group Preclinical Prodromal Dementia Thal1 Thal2 Thal3
40 to 44 24.01 0.13 0.00 23.07 1.68 1.11
45 to 49 5.61 0.31 0.00 5.61 2.58 0.68
50 to 54 7.53 0.64 0.16 7.53 4.98 1.54
55 to 59 18.51 1.45 0.46 18.51 10.00 2.44
60 to 64 27.60 3.49 0.70 27.60 16.98 3.32
65 to 69 32.76 7.65 1.87 32.76 18.13 7.08
70 to 74 10.43 16.24 4.22 10.43 28.14 12.14
75 to 79 10.34 32.65 7.50 10.34 28.72 14.21
80 to 84 10.10 57.29 15.27 10.10 10.51 20.27
85 to 89 13.80 16.98 35.33 13.80 11.22 26.84
90 to 94 12.09 22.32 61.83 12.09 12.09 36.26
>95 33.85 23.44 109.38 33.85 49.48 104.17
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would target subjects at the preclinical phase to avoid
progression to overt clinical AD and this objective could
be hypothetically achieved by risk-factor intervention or
disease-modifying therapies. In turn, interventions in
the prodromal stage would qualify as tertiary prevention
to target the delay or avoidance of dementia onset in
the presence of symptoms. In keeping with these defini-
tions and our results, the size of the population targets
would include the whole nondemented population for
primary prevention, 23.3% of that population older than
40 years for secondary prevention, and 14.2% older than
60 years for tertiary programs. The size of these target
populations constrains the viability of an ideal public
health perspective to reduce AD prevalence based on a
scalable approach, with interventions first targeting risk
factors and then pharmacologic treatment in a highly
selected group of individuals [9].
Much information has been gathered regarding the
role of vascular risk factors and certain lifestyle condi-
tions, such as low education, diet or sedentary behavior,
and their association with dementia in general and AD
in particular [32]. However, at present, no causal rela-
tionship has been demonstrated, and there is no evi-
dence that the reduction of risk factors directly results
in decreased incidence of either biomarker positivity or
clinical AD [11]. Prevention strategies with anti-amyloid
therapies have been proposed for asymptomatic individ-
uals with the genetic and sporadic forms of AD [33].
However, our findings suggest that pharmacologic inter-
ventions in subjects with preclinical sporadic AD are
hardly feasible. First, screening programs to detect amyloid
based on positron emission tomography are so farunaffordable, and those based on lumbar puncture are
invasive and need further standardization. Second, even
if a more accessible biomarker becomes available and a
therapy shows sufficient efficacy and safety, its applica-
tion would target the 50% of subjects older than 60
years who have amyloid deposits, 62% of whom would
never reach the dementia stage [34]. Overdiagnosis is a
concept borrowed from cancer-screening evaluation
that can also be applied to AD research; in this
situation, overdiagnosis describes those individuals
found to have AD by the presence of positive bio-
markers but who will never have symptoms [35]. The
risk of falling into the big prostate mistake has already
been highlighted [36].
Tertiary programs might hypothetically treat symp-
tomatic subjects with MCI due to AD to delay or pre-
vent progression to the dementia stage. According to
our data, it is still difficult to take a different approach
for people with MCI. Subjects with MCI are at a signifi-
cantly increased risk for the development of dementia
associated with AD [37], and therefore represent a target
population for preventive strategies. In our model, if the
intervention in 2010 had been limited to subjects older
than 60 years of age in the prodromal stage (MCI with
positive AD biomarkers), the size of the target popula-
tion would have been 14.2% (1,419,000 individuals).
However, to make the diagnosis in this population, sub-
jects with general MCI or MCI of any type should be
screened with the appropriate AD markers, but they are
not yet widely available. The size of the population with
general MCI limits the generalized use of biomarkers or
therapies and shows the need for more specificity in
identification of the target population. Identifying those
Table 4 Prevalence by age group and type of classification (clinical and pathological) in the Spanish population
Clinical classificationa Pathological classificationb
Age group Population Preclinical Prodromal Dementia Thal1 Thal2 Thal3
Number
40 to 44 2,981,900 252,700 800 0 253,500 16,900 9,400
45 to 49 3,530,900 388,400 4,900 0 393,300 47,200 19,800
50 to 54 3,109,400 431,800 9,400 1,100 442,300 93,600 31,600
55 to 59 2,620,100 517,600 19,400 3,200 540,200 172,400 49,900
60 to 64 2,438,200 739,200 43,500 9,200 791,900 336,900 82,400
65 to 69 2,091,000 929,800 79,800 17,800 1,027,400 461,000 120,900
70 to 74 1,705,800 817,900 148,900 31,300 998,100 583,200 178,600
75 to 79 1,653,700 699,100 291,800 58,200 1,049,100 814,400 266,400
80 to 84 1,218,300 329,500 418,600 90,500 838,600 709,500 277,300
85 to 89 659,500 67,200 330,800 90,400 488,400 416,600 195,600
90 to 94 215,100 14,100 97,300 52,200 163,600 136,000 74,700
>95 38,400 2,700 9,100 16,400 28,200 22,800 14,100
Total >40 22,262,300 5,190,000 1,454,300 370,300 7,014,600 3,810,500 1,320,700
Total >60 10,020,000 3,599,500 1,419,800 366,000 5,385,300 3,480,400 1,210,000
Percentage
40 to 44 100.0 8.5 0.0 0.0 8.5 0.6 0.3
45 to 49 100.0 11.0 0.1 0.0 11.1 1.3 0.6
50 to 54 100.0 13.9 0.3 0.0 14.2 3.0 1.0
55 to 59 100.0 19.8 0.7 0.1 20.6 6.6 1.9
60 to 64 100.0 30.3 1.8 0.4 32.5 13.8 3.4
65 to 69 100.0 44.5 3.8 0.9 49.1 22.0 5.8
70 to 74 100.0 47.9 8.7 1.8 58.5 34.2 10.5
75 to 79 100.0 42.3 17.6 3.5 63.4 49.2 16.1
80 to 84 100.0 27.0 34.4 7.4 68.8 58.2 22.8
85 to 89 100.0 10.2 50.2 13.7 74.1 63.2 29.7
90 to 94 100.0 6.6 45.2 24.3 76.1 63.2 34.7
>95 100.0 7.0 23.7 42.7 73.4 59.4 36.7
Total >40 100.0 23.3 6.5 1.7 31.5 17.1 5.9
Total >60 100.0 35.9 14.2 3.7 53.7 34.7 12.1
aData for clinical stages are not aggregated. bData for pathological classification prevalence are aggregated.
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marker positivity would help to select those at high risk
of rapid conversion to dementia. Improved predictive
values at early diagnosis would result in fewer treated
individuals who otherwise would never have had de-
mentia. It is true that this approach can be only specula-
tive before a disease-modifying treatment is available,
but subjects with MCI and a positive biomarker could
well be targeted in clinical trials with the already ap-
proved, cheaper cholinesterase inhibitors in an attempt
to delay onset of dementia [38]. The definition of MCI
from clinical studies has determined the super-selection
of patient groups at high risk of dementia [39], but direct
application of such data to population-based programsmay not be completely appropriate. On one hand, the
clinical course of MCI is not always progressive. On the
other, not all subjects in whom dementia develops have
previously fulfilled the diagnostic criteria for MCI [39].
One of the strengths of our work is the combination
of the two competitive risks that determine the epidemi-
ology of AD: time to onset of dementia and time until
death by other causes. The inclusion of age in the math-
ematical functions and the thorough validation process
(see Additional file 1) shows that our AD model has not
ignored the ‘elephant in the room’ analogy described by
Brayne in her seminal paper [40]. Our approach to AD
is a view extending over the patients’ lifetime and in-
corporating the long preclinical stage that can only be
Figure 2 Disaggregated prevalence by age group and by clinical
and pathological classification.
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We also acknowledge some limitations in our approach.
First, modeling findings should always be interpreted
with caution, because they are based on a mathematical
representation of the disease and not directly on empir-
ical data. However, our representation of the natural
history of AD is robust because it relies on an integra-
tive framework that includes clinical, neuropathological,
demographic and epidemiological elements. Second, we
did not address the current multifactorial expression of
the course of AD in late life in terms of cognitive im-
pairment and dementia [31]. Defining mathematical
functions to explore the role of vascular factors or other
comorbidities in the development of the early stages of
AD should be the object of further analysis. As an initial
approach, we have reproduced a pure AD model based
on Aβ deposition. However, we acknowledge that
understanding the role of vascular and lifestyle-related
factors is a key issue in the research agenda for demen-
tia prevention and including them will be an advance in
the mathematical representation of the natural history
of AD. Third, estimating the prevalence of the preclin-
ical and clinical stages from a model grounded in
neuropathological data confronts the problem of the
well-established lack of correlation between amyloid
neuropathological findings and clinical manifestations
[18,19]. However, our model is intended to provide epi-
demiological indicators to characterize the time from
the onset of AD-related changes in the brain until the
onset of clinical milestones, not to support or question
the pathogenic or bystander role of amyloid. Simulationmodels can integrate existing partial knowledge of pre-
clinical and prodromal phases of AD in joint represen-
tation of its natural history and assessment of the
impact of possible interventions in terms of health
benefit and economic burden. As has been noted in
other studies with different approaches, results of simu-
lation models show the lack of correlation between
clinical and pathological classifications [18,19]. Aβ
(Thal phase 1) is present in a significant percentage of
the population 65 to 70 years of age; it seems to increase
thereafter and plateau in the population aged 85 years
or older. These differences support the hypothesis that
Aβ accumulation is necessary, but insufficient alone, to
cause dementia; other factors including vascular condi-
tions, inflammation, brain reserve and cognitive reserve
are also involved.
Conclusions
These findings raise questions about the feasibility of
drug-based prevention strategies. Currently, screening
programs with biomarkers in the early stages of AD can-
not be applied to the one-half of the general population
older than 60 years of age. Intensive research regarding
risk factors is therefore needed, so that more affordable
strategies may be planned. More efficient criteria are
also needed to select those subjects with MCI who have
an increased probability of positive screening for bio-
markers (prodromal stage).
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